Novel Calculator Guides Treatment Choice in Esophageal Cancer


A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices.

A novel calculator can more easily identify which esophageal adenocarcinoma patients derive an overall survival benefit from neoadjuvant chemoradiation to help guide treatment choices, according to a new study.

Neoadjuvant chemoradiation is established practice for esophageal adenocarcinoma patients with locally advanced and/or node-positive tumors. The challenge for clinicians is to determine which esophageal cancer patients will derive benefit from neoadjuvant chemoradiation, which can lead to either a pathologic complete response or to persistent or even progressive disease.

Up to 70% of patients will be downstaged as a result of neoadjuvant chemoradiation, stated the researchers, led by Emmanuel Gabriel, MD, PhD, of the department of surgical oncology at Roswell Park Cancer Institute in Buffalo, New York. However, some patients do not benefit and neoadjuvant chemoradiation may even result in higher mortality.

Tools to predict which patients derive the most benefit from neoadjuvant chemoradiation “would therefore have much needed utility in the treatment of esophageal cancer,” they stated.

Using calculators to estimate outcomes and apply the results to real-time clinical situations can aid in treatment decision-making and to individualized therapy, they noted.

“Our effort is a good example of how you can use large national databases to create calculators to guide and improve preoperative decision-making. Such tools can help us, for example, to avoid the toxic side effects of upfront chemoradiotherapy in a subset of patients,” said senior author Moshim Kukar, MD, assistant professor of surgery in the department of surgical oncology at Roswell Park.

The researchers set out to create a tool to help identify which patients may benefit from treatment before surgery, noting that patients with advanced, aggressive tumors are often good pretreatment candidates.

They published their results online in the Journal of the American College of Surgeons.

Using the National Cancer Data Base, the researchers evaluated clinical data for 8,974 patients diagnosed with early-stage esophageal adenocarcinoma. The database records information for as many as 70% of the nation’s cancer cases through participating hospitals. They evaluated characteristics such as patients’ comorbidity score, tumor grade, and neoadjuvant chemoradiation status (whether they had chemotherapy and/or radiation prior to surgery).

To develop the calculator, they used preoperative data only.

The results show that those who received neoadjuvant chemoradiation had improved overall survival. The patients who benefited more from neoadjuvant chemoradiation included those whose tumors had metastasized to nearby lymph nodes, older patients and those with more aggressive cancers, such as tumors of higher grade and greater depth of invasion.

The researchers stated that “we developed an individualized overall survival calculator for esophageal adenocarcinoma that shows reasonable performance in identifying subsets of patients who would most benefit” from neoadjuvant chemoradiation.

Kukar noted that the “calculator should be validated prospectively before firm conclusions can be drawn about its value in treatment selection.”

The researchers plan to compare their calculator with the few existing calculators and to refine their prediction models as updated and more contemporary data are released from the National Cancer Data Base.

Related Videos
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.